Voya Investment Management LLC Sells 10,100 Shares of Krystal Biotech, Inc. $KRYS

Voya Investment Management LLC trimmed its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 13.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,601 shares of the company’s stock after selling 10,100 shares during the quarter. Voya Investment Management LLC owned about 0.22% of Krystal Biotech worth $11,648,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Brooklyn Investment Group increased its stake in Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after purchasing an additional 105 shares in the last quarter. Twin Tree Management LP bought a new stake in Krystal Biotech during the 1st quarter valued at about $29,000. Fifth Third Bancorp increased its stake in Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after purchasing an additional 105 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock valued at $58,000 after purchasing an additional 177 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Krystal Biotech during the 1st quarter valued at about $74,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Trading Down 0.9%

KRYS opened at $154.38 on Wednesday. The company has a market cap of $4.47 billion, a price-to-earnings ratio of 31.38 and a beta of 0.66. The company’s 50 day moving average is $147.35 and its 200 day moving average is $152.28. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $207.84.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.21. The company had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity

In related news, insider Suma Krishnan sold 13,435 shares of the firm’s stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares of the company’s stock, valued at approximately $216,924,382.80. This trade represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 49,800 shares of company stock valued at $7,487,943 over the last quarter. Company insiders own 13.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on KRYS. Bank of America reduced their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Chardan Capital reduced their price objective on shares of Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. Citigroup restated a “neutral” rating and set a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, HC Wainwright restated a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Monday. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and an average price target of $209.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).